Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

<br /> Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting<br />

PR Newswire

– Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation –

– Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented –

DUBLIN

,

May 9, 2022

/PRNewswire/ —

Alkermes plc

(Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place

June 3-7, 2022

in

Chicago

and virtually. The final dataset from the phase 1/2 ARTISTRY-1 clinical trial, evaluating the safety, tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA
^®
), will be shared in an oral presentation. In addition, trial-in-progress posters from the ongoing ARTISTRY-3 trial and the potential registration-enabling studies ARTISTRY-6 and ARTISTRY-7 will be presented.

Details of the presentations are as follows:

Oral Presentation

Abstract:

2500

Title:

Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1

Presenter:

Ulka N. Vaishampayan, M.D., Professor, Internal Medicine, Division of Hematology/Oncology,

University of Michigan

Presentation Session Date/Time:

The oral presentation will take place on

Saturday, June 4, 2022

from 1:15 –

4:15 p.m. CDT

, during the session titled “Developmental Therapeutics—Immunotherapy”

Poster Presentations

Abstract:

TPS5609

Title:

ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Presenter:

Thomas J. Herzog, M.D., Professor of Obstetrics and Gynecology, Deputy Director,

University of Cincinnati

Cancer Institute and Associate Director of GOG Partners

Presentation Session Date/Time:

The poster will be presented on

Saturday, June 4, 2022

from 1:15 –

4:15 p.m. CDT

, during the “Gynecologic Cancers” poster session

Abstract:

TPS2684

Title:

ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors

Presenter:

Sarina A. Piha-Paul, M.D., Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine,

University of Texas

MD Anderson Cancer Center

Presentation Session Date/Time:

The poster will be presented on

Sunday, June 5, 2022

from 8:00 –

11:00 a.m. CDT

, during the “Developmental Therapeutics—Immunotherapy” poster session

Abstract:

TPS9609

Title:

ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma

Presenter:

Jeffrey S. Weber, M.D., Ph.D., Professor of Medicine, Deputy Director, Laura and Isaac Perlmutter Cancer Center,

New York University

School of Medicine

Presentation Session Date/Time:

The poster will be presented on

Monday, June 6, 2022

from 1:15 –

4:15 p.m. CDT

, during the “Melanoma/Skin Cancers” poster session

About Nemvaleukin Alfa (nemvaleukin)

Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

About the ARTISTRY Clinical Development Program

ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA
^®
(pembrolizumab) in patients with advanced solid tumors. Ongoing trials in the ARTISTRY program include:

ARTISTRY-1

,

ARTISTRY-2

,

ARTISTRY-3

,

ARTISTRY-6

and

ARTISTRY-7

.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in

Dublin, Ireland

, Alkermes plc has a research and development center in

Waltham, Massachusetts

; a research and manufacturing facility in Athlone,

Ireland

; and a manufacturing facility in

Wilmington, Ohio

. For more information, please visit Alkermes’ website at

www.alkermes.com

.